FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.
Related Articles
Radiation-Associated Secondary Cancer in Patients With Breast Cancer
This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.
SCLC Staging Determines Treatment, Adverse Events
The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.
Telehealth speeds access to clinical trials for cancer
Physicians @OSUCCC_James are pioneering telehealth to give more patients access to lifesaving clinical trials.
Low-Risk Individuals Should Not Currently Be Screened for… : Oncology Times
An abstract is unavailable.
NCCN Expands Genetic Risk Assessment Guidelines to Include Additional Tumor Types
National Comprehensive Cancer Network updated 2 guideline resources to keep providers and other stakeholders up to date on cutting-edge genetic research.
Laying the groundwork for a new cancer-preventive vaccine
Three Fred Hutch Cancer Center researchers received a five-year, $3.8 million award from the National Cancer Institute to delve into the “black box” of our…
Blinatumomab and TKI Combination Therapy Safe and Effective for Treatment of ALL – Oncology Nurse Advisor
The development of tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, and ponatinib, has revolutionized the treatment of Ph+ ALL.
Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors
Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.
The use of gilteritinib in post-transplant maintenance for AML with FLT3-ITD
Mark Levis, MD, PhD, John Hopkins University, Baltimore, MD, highlights the favorable tolerability of gilteritinib compared to other FLT3 inhibitors in the post-transplant setting for…
Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC
David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.